title: Resting energy expenditure and the clearance of therapeutic proteins in pediatric subjects.
abstract: The effect of age on the clearance (CL) of therapeutic proteins has not been explored extensively in pediatric subjects. Recently, resting energy expenditure (REE) has been proposed to link age-dependent CL with developmental changes. Allometric relationship was explored to assess the impact of REE on the CL of therapeutic proteins in pediatric subjects. The CL of a therapeutic protein estimated from allometric scaling using REE was approximately 2-fold higher than that using body weight (BW) in younger children. For some monoclonal antibodies, REE was a better predictor than BW to estimate CL in pediatric subjects. Overall results suggest that the relationship of CL with REE and its clinical importance in therapeutic proteins need to be investigated further for pediatric subjects.
authors.affiliation: Covance Laboratories, Madison, Wis., USA.
authors.forename: Sun Ku
authors.initials: SK
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000375:Aging / Q000502:physiology*; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics*; D000077552:Basiliximab; D001827:Body Height; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D000077561:Daclizumab; D004734:Energy Metabolism; D006801:Humans; D007074:Immunoglobulin G; D000069285:Infliximab; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000069285:Infliximab; D000077561:Daclizumab